Important pharmacy news and late-breaking industry information updated daily.
New York state officials have said the cystic fibrosis drug ivacaftor–lumacaftor (Orkambi—Vertex Pharmaceuticals), which costs $272,000 a year but has been shown to only modestly help patients, is not worth its price, and are demanding that Vertex give a steeper discount to the state's Medicaid program.
The Trump administration has proposed transferring most of the responsibility for regulating food safety from FDA to the Department of Agriculture (USDA), and to rename FDA the "Federal Drug Administration." The proposal is part of a plan released Thursday that includes other broader ideas to reform HHS, including renaming it the "Department of Hea
There is growing support to allow pharmacists to prescribe medications, according to a <I>British Journal of Clinical Pharmacology</I> review of a large number of studies in many countries.
CVS Health has reached a deal with the U.S. Postal Service to pick up prescriptions at CVS stores and bring them to customers' homes in 1 or 2 days. Customers will be charged $4.99 per delivery, which could include OTC products as well.
FDA Commissioner Scott Gottlieb, MD, is being urged to give Congress recommendations on how deal with drug shortages across the United States. A bipartisan group of senators, led by Sens.
JAPhA study: Older patients, patients on more than five medications more likely to have prescribing cascades
Pharmacist and student pharmacist attendees tackle addiction and recovery
FDA approved Thursday the first generic versions of buprenorphine and naloxone (Suboxone—Indivior) sublingual film for the treatment of opioid dependence. Mylan Technologies and Dr. Reddy's Laboratories received FDA approval to market buprenorphine and naloxone sublingual film in multiple strengths.
West Virginia Attorney General Patrick Morrisey is calling on doctors and pharmacists in the state to support a new anti-retaliation law to alleviate any negative consequences for doctors who follow their best medical judgment and refuse to prescribe opioids.
HHS Secretary Alex Azar on Tuesday told the Senate Committee on Health, Education, Labor, and Pensions that several drug companies are looking at "substantial and material" price cuts. He said in testimony before the committee that companies are working with PBMs to make sure "they are not discriminated against" for cutting their prices.